Sjögren's Syndrome: Extraglandular Manifestations
Sjögren's syndrome causes significant extraglandular disease affecting the lungs, joints, skin, and heart in approximately one-third of patients, with pulmonary involvement being the most clinically important due to its impact on mortality and requiring systematic screening and monitoring.
Pulmonary Manifestations
Clinical Spectrum and Prevalence
Pulmonary complications occur in 9-27% of patients with Sjögren's disease and represent the most critical extraglandular manifestation affecting prognosis 1, 2. The respiratory system can be affected across multiple levels:
- Airways disease: Xerotrachea (drying of tracheal mucosa), bronchial hyperreactivity, bronchiolitis, and bronchiectasis
- Interstitial lung disease (ILD): The most serious pulmonary complication
- Cystic lung disease: Progressive and potentially severe
- Lymphoproliferative disorders: Including MALT lymphoma and pulmonary lymphoma
Key Clinical Features
Cough is the most common pulmonary symptom, occurring in >50% of patients 3. The pathogenesis involves:
- Desiccation of upper airway mucosa (xerotrachea)
- Bronchial hyperreactivity (present in 60% of patients, with 83% experiencing nonproductive cough)
- Lymphocytic inflammation causing bronchial gland dysfunction
Screening and Monitoring Protocol
All Sjögren's patients require detailed respiratory history at initial and every subsequent visit 1. For asymptomatic patients:
- Baseline chest radiograph may be performed to identify subclinical involvement 1
- High-resolution CT (HRCT) is preferred when concern for lung involvement is high due to superior sensitivity 1
- Complete pulmonary function tests (PFTs) should include:
- Pre- and post-bronchodilator spirometry
- Diffusing capacity (DLCO)
- Lung volumes by body plethysmography
- Repeat every 3-6 months, especially in first 1-2 years 1
Disease Severity Staging
Based on EULAR Sjögren's Syndrome Disease Activity Index 1:
Moderate disease:
- Shortness of breath on exercise (NYHA II)
- FVC 60-80% predicted OR DLCO 40-70% predicted
Severe/high disease:
- Shortness of breath at rest (NYHA III-IV)
- FVC <60% predicted OR DLCO <40% predicted
Treatment Algorithm for Sjögren's-ILD
For symptomatic patients with moderate-severe disease 1:
First-line: Moderate-dose oral corticosteroids (≤60 mg prednisone daily with slow taper over weeks-months)
Steroid-sparing maintenance therapy (when unable to taper or long-term therapy predicted):
- Mycophenolate mofetil (MMF) or azathioprine as first-line agents
- Consider rituximab or cyclophosphamide for refractory cases
Progressive fibrotic ILD: Add nintedanib (FDA-approved antifibrotic) as second-line maintenance therapy, alone or combined with immunomodulatory agents 1
Rapidly progressive or acute respiratory failure:
- High-dose IV methylprednisolone or oral corticosteroids up to 60 mg prednisone daily
- Add rituximab or cyclophosphamide to high-dose corticosteroids
- Consider lung transplant evaluation 1
Critical Safety Considerations
Multiple medications used to treat Sjögren's can paradoxically cause drug-induced ILD (risk ~1%) 1:
- TNF-alpha inhibitors
- Methotrexate
- Leflunomide
- Rituximab
- Cyclophosphamide
- Sulfasalazine
- Sulfonamides
Lymphoma surveillance is mandatory: Investigate unexplained weight loss, fevers, night sweats, lymphadenopathy, or parotitis 1. HRCT is preferred over chest X-ray when lymphoproliferative disease is suspected.
Joint Manifestations
Arthralgia and myalgia are common systemic symptoms in Sjögren's syndrome 4, 5. The main diagnostic challenge occurs when patients present with:
- Arthritis: Can overlap with rheumatoid arthritis, making differentiation difficult
- Raynaud phenomenon: May suggest overlap with systemic sclerosis or mixed connective tissue disease
Approximately 10-20% of primary Sjögren's patients have atypical autoantibodies (antiphospholipid antibodies, ANCA) that can suggest overlap syndromes, though actual coexisting diseases occur in only ~10% of these cases 5.
Skin Manifestations
Cutaneous features that create diagnostic overlap include 5:
- Purpura: May indicate cryoglobulinemic vasculitis
- Subacute cutaneous lupus erythematosus: Suggests possible SLE overlap
- Livedo reticularis: Associated with antiphospholipid antibodies
- Erythema nodosum: Nonspecific inflammatory manifestation
These skin findings often overlap with other systemic autoimmune diseases, making classification challenging.
Cardiac Manifestations
Cardiac involvement in Sjögren's syndrome is rare but increasingly recognized as contributing to cardiovascular morbidity and mortality 6. While not conventionally considered a disease feature, recent studies show patients have greater overall risk of cardiovascular events.
Potential cardiac manifestations include:
- Pericardial disease
- Myocarditis
- Conduction abnormalities
- Heart failure
- Coronary artery disease (accelerated atherosclerosis)
Consider echocardiogram if pulmonary hypertension is suspected in patients with ILD 1.
Important Clinical Pitfall
Rituximab, commonly used for systemic manifestations, carries cardiac risks including arrhythmias and angina 1. Hydroxychloroquine, frequently prescribed, can cause cardiomyopathy with long-term use 7.
Management Principles
For systemic manifestations, hydroxychloroquine and leflunomide form the backbone of therapy 8, 9. The 2020 EULAR recommendations emphasize:
- Hydroxychloroquine: First-line for systemic disease activity
- Leflunomide, iguratimod, or tripterygium glycosides: For moderate disease
- Rituximab: Reserved for refractory cases or severe organ involvement
- Cyclophosphamide or mycophenolate mofetil: For life-threatening manifestations
Pregnant patients with anti-SSA antibodies require specialized multidisciplinary care due to risk of neonatal lupus and congenital heart block 9.
Co-management Requirements
All Sjögren's patients should be co-managed with rheumatology due to multiple possible comorbid systemic conditions, risk of lymphoproliferative disorders (standardized incidence ratio 7-48 for B-cell lymphoma), and potential for life-threatening vasculitic complications 4, 8.